Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-2807
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma ; day:15 ; month:4 ; year:2020 ; pages:1-7
Pathology & oncology research ; (15.4.2020), 1-7
- Creator
-
Géczi, Lajos
Bodoky, György
Rokszin, György
Fábián, Ibolya
Torday, László
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12253-020-00809-z
- URN
-
urn:nbn:de:101:1-2020062812033094705918
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Géczi, Lajos
- Bodoky, György
- Rokszin, György
- Fábián, Ibolya
- Torday, László
- SpringerLink (Online service)
Other Objects (12)
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Second-line Therapien bei malignen biliären Tumoren
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
Sirolimus as a second-line treatment for Graves’ orbitopathy
Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Second-line Therapien bei malignen biliären Tumoren
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
Sirolimus as a second-line treatment for Graves’ orbitopathy
Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Second-line Therapien bei malignen biliären Tumoren
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
Sirolimus as a second-line treatment for Graves’ orbitopathy
Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock